Skip to main content
. 2021 Apr 30;51(2):440–447. doi: 10.3906/sag-2005-57

Table 3.

Treatment, complications, and clinical outcome of the patients.

Characteristic Patients(n = 103)
Treatment
Oxygen inhalation, n (%) 41 (39.8%)
Invasive mechanic ventilation, n (%) 62 (60.2%)
Discharged from ICU, n (%) 1 (1.6%)
Died, n (%) 47 (75.8%)
Remained in ICU, n (%) 14 (22.5%)
Vasopressor, n (%) 47 (45.6%)
Continuous renal replacement therapy, n (%) 21 (20.4%)
Blood purification treatment, n (%) 4 (3.9%)
Hydroxychloroquine, n (%) 103 (100%)
Favipiravir, n (%) 52 (50.5%)
Lopinavir/Ritonavir, n (%) 40 (38.8%)
Steroids, n (%) 63 (61.2%)
Tracheostomy, n (%) 2 (1.9%)
Prone positioning, n (%) 45 (43.6%)
Complications
ARDS, n (%) 63 (61.2%)
Acute kidney injury, n (%) 31 (30.1%)
MODS, n (%) 52 (50.5%)
Clinical outcome
Median length of stay in ICU (IQR), days
All patients 7 (5–12)
Died 7 (4–10)
Discharged 6 (3.8–10.2)
Discharged from ICU, n (%) 30 (29.1%)
Died, n (%) 52 (50.5%)
Remained in ICU, n (%) 21 (20.4%)

ARDS: acute respiratory distress syndrome, MODS: multiple organ dysfunction 364 syndrome, ICU: intensive care unit. IQR: interquartile range.